- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265511
Study of SCY-635, Pegasys and Copegus in Hepatitis C
A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
The primary objective of this Phase 2a study was to assess the effect of treatment with SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.
The secondary objective of the study was to evaluate the safety and pharmacokinetics (PK) of SCY-635 when given in combination with PegIFN α-2a and RBV.
Primary Endpoints:
Proportion of subjects in each cohort with an undetectable serum HCV RNA level at Week 4 of treatment
Secondary Endpoints:
Adverse events and clinical laboratory assessments, including tests of liver function Proportion of subjects achieving complete early virologic response (cEVR, defined as an undetectable serum HCV RNA level at Week 12) Proportion of subjects achieving partial early virologic response (pEVR, defined as a detectable serum HCV RNA level with ≥ 2 log10 reduction in serum HCV RNA from Baseline to Week 12) Proportion of subjects achieving an undetectable serum HCV RNA level at Week 24 Pharmacokinetic assessments of SCY-635 when given in combination with PegIFN α-2a and RBV; trough concentrations of PegIFN α-2a and RB
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion de Investigation de Diego
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Quest Clinical Research
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Alamo Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL
- Chronic HCV status
- HCV genotype 1 infection and IL28B genotype of C/T or T/T
Liver biopsy results within 3 years prior to screening indicating the absence of cirrhosis
*If no previous biopsy is available, a biopsy must be performed during the screening period to qualify for randomization
- Body mass index (BMI) between 18 and 38 kg/m2
Laboratory variables within acceptable ranges:
- ALT/AST < 3 × ULN;
- HgB > 12g/dL for females, > 13 g/dL for males;
- total WBC count > 3000/mm3 and ANC > 1500/mm3;
- platelets > 100,000/mm3;
- prothrombin time (or INR) ≤ 1.2 × ULN;
- serum albumin ≥ 3.4 g/dL;
- total bilirubin WNL;
- serum creatinine WNL; if serum creatinine is > ULN, then calculated creatinine clearance must be > 100 mL/min (by Cockcroft-Gault formula) for subject to be eligible
- Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal) must agree to use 2 forms of contraception from Screening until 24 weeks after completion of treatment with RBV
- Negative urine testing for amphetamines and cocaine at Screening.
- If female, the subject has a negative pregnancy test at Screening and on study Day 1
Exclusion Criteria:
- History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease
- Females who are pregnant or breastfeeding
- Males with partners who are pregnant or are planning to become pregnant
- HCV genotype other than genotype 1 and an IL28B genotype of C/C
- Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg)
- Use of any investigational agent within 3 months prior to dosing
- Received any prior FDA-approved or investigational drug or drug regimen for the treatment of hepatitis C
- Evidence of cirrhosis on a previous liver biopsy
- Evidence of decompensated liver disease
- Recipient of an organ transplant
- Evidence of hepatocellular carcinoma
- Evidence of ongoing alcohol or substance abuse
- Poorly-controlled diabetes mellitus
- Congestive heart failure or unstable cardiopulmonary condition, renal disease, or hemoglobinopathy (sickle cell anemia or thalassemia
- History of seizure disorder
- History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or psychosis requiring medication
- Concurrent medical condition or laboratory abnormality that would constitute a contra-indication for interferon use
- History of unstable thyroid disease that would preclude administration of interferon-based therapy
- Medical condition that requires use of systemic corticosteroids
- Received warfarin or other anticoagulants during the 21 days immediately prior to Screening, or is expected to require warfarin or other anticoagulants during the study.
- One or more additional known primary or secondary causes of liver disease, other than hepatitis C
- Any other concurrent medical condition likely to preclude compliance with the schedule of evaluations, or likely to confound the efficacy or safety observations
12-lead ECG showing the following:
- Corrected QTc interval ≥ 450 msec (Bazett's correction);
- QRS > 120 msec;
- Clinically significant abnormalities;
- Severe retinopathy or other significant ophthalmological disorder
- Use of any herbal supplements within 28 days prior to dosing.
- The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of treatment through Week 6
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
|
Oral tablets given bid for 28 days
Other Names:
180 ug prefilled syringe given once per week for up to 48 weeks
tablets given bid for up to 48 weeks
|
Active Comparator: SCY-635 600 mg
SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
|
180 ug prefilled syringe given once per week for up to 48 weeks
tablets given bid for up to 48 weeks
SCY-635 tablets, 300 mg bid for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Undetectable HCV RNA
Time Frame: Week 4
|
Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Undetectable HCV RNA
Time Frame: Week 24
|
Week 24
|
|
Undetectable HCV RNA
Time Frame: Week 12
|
Week 12
|
|
Partial Early Virologic Response
Time Frame: Week 12
|
Proportion of subjects with detectable HCV RNA that achieve a > or = 2 log reduction in HCV RNA from baseline to Week 12
|
Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrew J Muir, MD, Duke Clinical Research Institute
- Principal Investigator: Keyur Patel, MD, Duke Clinical Ressearch Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Peginterferon alfa-2a
Other Study ID Numbers
- SCY-635-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Infection
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityRecruitingChronic Hepatitis C InfectionChina
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedChronic Hepatitis C InfectionNew Zealand
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States